首页|不同治疗时机静脉溶栓联合血管内治疗急性缺血性脑卒中患者的疗效

不同治疗时机静脉溶栓联合血管内治疗急性缺血性脑卒中患者的疗效

扫码查看
目的 比较不同治疗时机静脉溶栓联合血管内治疗急性缺血性脑卒中(acute ischemic stroke,AIS)患者的疗效和对预后的影响.方法 选取 2021 年 7 月至 2023 年 9 月温州市中心医院收治的 180 例AIS患者为研究对象,根据患者发病后溶栓时间不同将其分为A组(2h内溶栓)、B组(2~3h内溶栓)、C组(3~4.5h溶栓)、D组(4.5~6h溶栓)和E组(6~9h溶栓),每组各 36 例.所有患者均进行阿替普酶静脉溶栓联合血管内治疗.比较各组患者的血管再通情况、神经功能、预后情况、日常生活能力和并发症发生情况.结果 五组患者的血管再通率比较差异有统计学意义(χ2=11.500,P=0.022),E组患者的血管再通率显著低于其余四组(P<0.05),D组患者的血管再通率显著低于A组、B组、C组(P<0.05).溶栓后,各组患者的美国国立卫生研究院卒中量表(National Institutes of Health stroke scale,NIHSS)评分、改良Rankin量表(modified Rankin scale,mRS)评分均随时间延长显著降低(P<0.05).溶栓后不同时间,E组患者的NIHSS评分、mRS评分均显著高于其余四组,D组患者的NIHSS评分、mRS评分均显著高于A组、B组、C组(P<0.05).溶栓后,各组患者的Barthel指数(Barthel index,BI)均随着时间延长明显升高(P<0.05).溶栓后不同时间,E组患者的BI评分均显著低于其余四组,D组患者的BI评分均显著低于A组、B组和C组(P<0.05).溶栓后 90d内,五组患者的颅内出血、口腔出血、院内感染、脑疝等并发症发生率比较差异均无统计学意义(χ2=1.356,P=0.852).结论 4.5h内对AIS患者行阿替普酶静脉溶栓联合血管内治疗的临床疗效更佳,患者预后水平更好.
Efficacy of intravenous thrombolysis combined with intravascular therapy in patients with acute ischemic stroke at different treatment times
Objective To compare the efficacy of intravenous thrombolysis combined with intravascular therapy for patients with acute ischemic stroke(AIS)from different treatment opportunities and its impact on prognosis.Methods A total of 180 AIS patients admitted to Wenzhou Central Hospital from July 2021 to September 2023 were selected as study objects,and divided into group A(thrombolysis within 2h),Group B(thrombolysis within 2-3h),group C(thrombolysis within 3-4.5h),group D(thrombolysis within 4.5-6h)and group E(thrombolysis within 6-9h)according to different thrombolysis times after owset.There were 36 cases in each group.All patients received alteplase intravenous thrombolysis combined with intravascular therapy.Vascular recanalization,neurological function,prognosis,ability of daily living and complications were compared among all groups.Results Vascular recanalization rate of five groups had statistical significance(χ2=11.500,P=0.022).Vascular recanalization rate of group E was significantly lower than that of other four groups(P<0.05),and vascular recanalization rate of group D was significantly lower than that of groups A,B and C(P<0.05).After thrombolysis,National Institutes of Health stroke scale(NIHSS)score and modified Rankin scale(mRS)score of patients in all groups were significantly decreased with the extension of time(P<0.05).At different time after thrombolysis,NIHSS score and mRS score in group E were significantly higher than those in other four groups,and NIHSS score and mRS score in group D were significantly higher than those in groups A,B and C(P<0.05).After thrombolysis,Barthel index(BI)of all groups increased significantly with the extension of time(P<0.05).At different time after thrombolysis,BI score of group E were significantly lower than those of other four groups,and BI score of group D were significantly lower than those of groups A,B and C(P<0.05).Within 90 days after thrombolysis,there was no significant difference in the incidence of intracranial hemorrhage,oral hemorrhage,nosocomial infection and cerebral hernia among five groups(χ2=1.356,P=0.852).Conclusion Alteplase intravenous thrombolysis combined with intravascular therapy in AIS patients within 4.5h has better clinical efficacy and better prognosis.

AlteplaseAcute ischemic strokeIntravenous thrombolysisIntravascular therapy

潘学威、李志伟、朱荷燕、茅新蕾、黄向东

展开 >

温州市中心医院神经内科,浙江温州 325000

温州市中心医院神经外科,浙江温州 325000

温州泛血管疾病管理中心实验室,浙江温州 325000

阿替普酶 急性缺血性脑卒中 静脉溶栓 血管内治疗

浙江省温州市基础科研项目

Y20220826

2024

中国现代医生
中国医学科学院

中国现代医生

影响因子:1.571
ISSN:1673-9701
年,卷(期):2024.62(16)
  • 14